MedPath

iCAD Inc

🇺🇸United States
Ownership
-
Employees
69
Market Cap
$41.3M
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

No trials found

News

Medical Horizons Partners with Bowhead Health to Expand AI-Powered Clinical Trial Matching Across Italy, Turkey, and Cyprus

Medical Horizons S.r.l. has secured an exclusive distribution agreement with Canadian company Bowhead Health Inc. to bring AI-powered clinical trial matching technology to Italy, Turkey, and Cyprus.

RadNet to Acquire iCAD for $100 Million, Advancing AI-Powered Breast Cancer Detection

RadNet Inc. has announced plans to acquire iCAD Inc. for approximately $100 million, uniting two leading companies in AI-powered cancer detection technology with a focus on breast cancer screening.

iCAD and Koios Medical Unite to Launch Comprehensive AI-Powered Breast Cancer Detection Platform

iCAD and Koios Medical announce strategic partnership to integrate ProFound AI Breast Health Suite with Koios SmartUltrasound, creating a comprehensive AI-powered breast cancer detection solution.

iCad's AI-Powered Breast Cancer Detection Tech ProFound Detection version 4.0 Receives FDA Clearance

iCad's ProFound Detection version 4.0, an AI-powered solution for digital breast tomosynthesis (DBT), has received FDA clearance, marking a significant advancement in cancer detection technology.

iCAD's ProFound Detection 4.0 Receives FDA Clearance for Enhanced Breast Cancer Detection

iCAD's ProFound Detection Version 4.0, an AI-powered solution for digital breast tomosynthesis, has received FDA clearance, enhancing cancer detection and specificity.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.